GeoVax Labs (GOVX) director gets grant of 6,000 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
GeoVax Labs director Dean G. Kollintzas received a grant of 6,000 stock options on common stock. The options have a conversion or exercise price of $1.18 per share and relate to 6,000 underlying common shares. They expire on June 17, 2036, and his derivative holdings after this award total 6,000 options held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Kollintzas Dean G
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 6,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option — 6,000 shares (Direct, null)
Footnotes (1)
Key Figures
Stock options granted: 6,000 options
Exercise price: $1.18 per share
Underlying common shares: 6,000 shares
+2 more
5 metrics
Stock options granted
6,000 options
Grant to director Dean G. Kollintzas on June 17, 2026
Exercise price
$1.18 per share
Conversion or exercise price of granted stock options
Underlying common shares
6,000 shares
Shares of GeoVax common stock underlying the options
Expiration date
June 17, 2036
Last date the 6,000 stock options can be exercised
Total derivative holdings after grant
6,000 options
Total stock options held directly following the transaction
Key Terms
Stock Option, conversion or exercise price, expiration date
3 terms
Stock Option financial
"security_title: "Stock Option" linked to GeoVax common stock"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
conversion or exercise price financial
"conversion_or_exercise_price set at 1.1800 per share"
expiration date financial
"expiration_date listed as 2036-06-17T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What insider transaction did GeoVax Labs (GOVX) report for Dean G. Kollintzas?
GeoVax Labs reported that director Dean G. Kollintzas received a grant of 6,000 stock options. These options relate to the company’s common stock and are recorded as a derivative acquisition rather than an open-market purchase, reflecting a compensation-related award.
How many stock options were granted to the GeoVax (GOVX) director and at what price?
Dean G. Kollintzas was granted 6,000 stock options on GeoVax common stock. The conversion or exercise price for these options is $1.18 per share, meaning this is the price he would pay per share if he exercises the options in the future.
When do Dean G. Kollintzas’s GeoVax (GOVX) stock options expire?
The 6,000 stock options granted to Dean G. Kollintzas expire on June 17, 2036. This expiration date defines the last day he can exercise the options to purchase GeoVax common shares at the fixed $1.18 per-share exercise price.
Is the GeoVax (GOVX) Form 4 transaction a market purchase or a compensation award?
The Form 4 transaction is a compensation-related award, not a market purchase. It is coded as a grant or award acquisition, with 6,000 stock options issued at a $1.18 exercise price and a reported transaction price of $0.00 per option at grant.
What are Dean G. Kollintzas’s derivative holdings in GeoVax (GOVX) after this option grant?
After the grant, Dean G. Kollintzas holds 6,000 derivative securities linked to GeoVax common stock. The filing shows total shares following the transaction of 6,000 stock options, all held directly, with no additional derivative positions listed in the derivative summary.